India · Delayed Price · Currency is INR Venus Remedies Statistics
Total Valuation
Venus Remedies has a market cap or net worth of INR 6.31 billion. The enterprise value is 4.76 billion.
| Market Cap | 6.31B |
| Enterprise Value | 4.76B |
Important Dates
The last earnings date was Monday, August 4, 2025.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 13.37M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.47% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 6.79M |
Valuation Ratios
The trailing PE ratio is 11.75.
| PE Ratio | 11.75 |
| Forward PE | n/a |
| PS Ratio | 0.94 |
| PB Ratio | 1.12 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 8.87 |
| EV / Sales | 0.71 |
| EV / EBITDA | 7.16 |
| EV / EBIT | 9.79 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | n/a |
| Interest Coverage | 878.07 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 5.57% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 5.17M |
| Profits Per Employee | 413,673 |
| Employee Count | 1,298 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Venus Remedies has paid 238.92 million in taxes.
| Income Tax | 238.92M |
| Effective Tax Rate | 30.79% |
Stock Price Statistics
The stock price has increased by +20.52% in the last 52 weeks. The beta is 0.44, so Venus Remedies's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +20.52% |
| 50-Day Moving Average | 477.19 |
| 200-Day Moving Average | 357.42 |
| Relative Strength Index (RSI) | 42.41 |
| Average Volume (20 Days) | 15,841 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Venus Remedies had revenue of INR 6.71 billion and earned 536.95 million in profits. Earnings per share was 40.09.
| Revenue | 6.71B |
| Gross Profit | 2.75B |
| Operating Income | 486.45M |
| Pretax Income | 775.87M |
| Net Income | 536.95M |
| EBITDA | 665.29M |
| EBIT | 486.45M |
| Earnings Per Share (EPS) | 40.09 |
Balance Sheet
The company has 1.56 billion in cash and 16.93 million in debt, giving a net cash position of 1.55 billion.
| Cash & Cash Equivalents | 1.56B |
| Total Debt | 16.93M |
| Net Cash | 1.55B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.61B |
| Book Value Per Share | 419.65 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 40.91%, with operating and profit margins of 7.25% and 8.00%.
| Gross Margin | 40.91% |
| Operating Margin | 7.25% |
| Pretax Margin | 11.56% |
| Profit Margin | 8.00% |
| EBITDA Margin | 9.91% |
| EBIT Margin | 7.25% |
| FCF Margin | n/a |
Dividends & Yields
Venus Remedies does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.47% |
| Shareholder Yield | n/a |
| Earnings Yield | 8.51% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |